• Corporate
• Markets
• Info-Tech
• Marketing
• Money & Banking
• Agri-Biz & Commodities
• Industry & Economy
• Logistics
• Government
• Opinion
• Variety
• Corporate Results
• Columns
• States
• Web Extras
• Index

• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

• Rates

• Ports

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Subscription

• Business Line

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

MUMBAI: Drug major Piramal Group on Thursday listed its research and development arm Piramal Life Sciences on the Bombay Stock Exchange at Rs 300 per share.

Piramal Life Sciences was recently demerged from Nicholas Piramal India Ltd. The demerged entity would take care of all the research and development of new drugs.

"We have 14 molecules in Piramal Life Sciences, of which six are in clinical trials. Two more would enter clinical trials in this year," Mr Ajay Piramal, Chairman, Piramal Life Sciences said here.

Piramal Life Sciences is looking to launch a drug either in cancer, diabetes, and infectious disease or inflammation in the market in 2010-11. - PTI

Prev: India Inc mops up $4.2 bn via IPOs so far in 2008
Next: India-focused cos cross $6 b market cap on AIM

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line